Navigation Links
Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
Date:3/7/2013

KANSAS CITY, Kan. and BOSTON, March 7, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has closed on a $10 million non-dilutive financing with Square 1 Bank, a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion.  Proceeds will be used to fund general corporate purposes. 

"We are delighted to have the continued support of Square 1 Bank," stated Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics.  "We're grateful Square 1 has remained a supporter of Aratana since its inception and are eager to extend our relationship as we advance our programs."

Scott Foote , senior vice president in Square 1 Bank's Life Sciences practice, added, "We are pleased to provide Aratana with the financing solutions it needs to support future developments in the animal health market, and we look forward to the company's future success."

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

About Square 1 Bank

Square 1 Bank is a full service commercial ban
'/>"/>

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. Nasseo, Inc. Joins BioInspireâ„¢ Medical Technology Incubator, Closes Seed Funding Round
5. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
6. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
7. Enviva Closes on $120 Million Senior Secured Credit Facility
8. AyoxxA Biosystems Closes Series A Financing Round
9. OncoSec Closes $7.75 Million Public Offering
10. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... March 13 Innocoll, Inc., a,privately-held biopharmaceutical ... of planned phase 2 clinical trials sponsored ... to investigate CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the ... Innocoll,s BUPIVACAINE SURGICAL IMPLANT is a biodegradable ...
... scientists worldwide gain new insight ... funding support for human brain, spinal cord and developing ... brain projects, ... it is undertaking three major projects designed to,accelerate brain, and spinal cord research, ...
... 93.3%; Full Year Net Income up 283.0%, SHANGHAI, ... WX ), the leading global pharmaceutical,biotechnology and medical ... its unaudited financial results for the,fourth quarter and full ... 2007 Highlights:, Compared to the fourth quarter 2006 ...
Cached Biology Technology:Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 2Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 3Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 12
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... (WSU) Laboratory for Atmospheric Research is leading a nationwide ... the distribution of natural gas. Beginning this month, ... Lamb will quantify methane emissions throughout local gas systems ... data to estimate a national methane emissions rate for ...
... the University of Michigan have identified a new potential ... alternative or complementary therapy to statins. Scientists ... Sciences Institute inhibited the action of a gene responsible ... of the liver to remove cholesterol from the blood ...
... animals are frequently observed scavenging on other animals whether it ... or a buzzard swooping down on a dead animal. However, ... difficult, and often overlooked in marine food web studies. , ... titled, " White sharks ( Carcharodon carcharias ) scavenging on ...
Cached Biology News:Methane emissions from natural gas local distribution focus of new study 2Methane emissions from natural gas local distribution focus of new study 3U-M researchers find new way to clear cholesterol from the blood 2Great white sharks 2
... laboratories working in a regulated environment, ... pipette calibration software that automates gravimetric ... a framework that meets todays regulatory ... a secure solution that includes a ...
... Vtg in plasma from juvenile or male fish ... disrupting chemicals (EDCs) with estrogenic effects in fish. ... test for the estrogenic effects of EDCs in ... a double-antibody immunometric (sandwich) EIA for analyzing Vtg ...
... Routine Testing Laboratory (RTL) can provide ... 25 years. ,,Microbial method development and ... monitor the conditions of your GMP ... manufactured products,,We offer a full spectrum ...
... PEP-152 is a 17 amino acid synthetic peptide whose sequence is ... (amino to carboxy terminus): C - N(217) - Q - ... - A - T - P - N - Y - ... may be used for neutralization and control experiments with the polyclonal ...
Biology Products: